AVEO Pharmaceuticals, Inc. (AVEO)

AVEO was delisted on the 19th of January, 2023.

• Market cap: $521M
• Sector: Healthcare
• Industry: Drug Manufacturers - General

About: AVEO Pharmaceuticals Inc is a commercial-stage, oncology-focused biopharmaceutical company engaged in offering medicines that provide a better life for patients with cancer. The company markets FOTIVDA (tivozanib) in the United States. FOTIVDA is an oral, next-generation vascular endothelial growth factor receptor, or VEGFR, tyrosine kinase inhibitor, or TKI. The group primarily operates in the U.S.

Employees: 115